Please ensure Javascript is enabled for purposes of website accessibility

Moderna's Vaccine Program News Overshadows Its Earnings Report

By Jim Crumly – Feb 26, 2020 at 3:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The financials were a sideshow as investors focused on the company's potential vaccines for the COVID-19 coronavirus and congenital cytomegalovirus.

Shares of Moderna (MRNA -0.55%) soared 19% to an all-time high Wednesday after the clinical-stage biotech reported earnings. Revenues of $14.1 million from collaborations and grants fell short of the $17.4 million that analysts were expecting, but investors weren't all that interested in last quarter's numbers. What drew the lion's share of attention were new details about progress in the company's core vaccine franchise: Analysts on the conference call were riveted to news about two important pipeline candidates.

Top-of-mind for investors was Monday's announcement that the first shipment of its experimental mRNA vaccine for SARS-CoV-2, the virus that causes COVID-19, had been sent to researchers with the National Institute of Allergy and Infectious Diseases.

Analysts on the call peppered Moderna executives with questions about the path forward for the vaccine, called mRNA-1273, but the company was short on answers. The National Institutes of Health (NIH) will be conducting the human trials for mRNA-1273, and the regulatory process for approving a vaccine in the face of an ongoing pandemic threat is simply unknown. For its part, Moderna is looking into how to scale up its manufacturing to meet the demand if its vaccine is proven effective soon.

Depiction of coronavirus cells.

Image source: Getty Images.

Also attracting attention was Moderna's update on mRNA-1647, its vaccine for congenital cytomegalovirus (CMV) and the most advanced mRNA-based vaccine candidate of the four that it has in human clinical trials. CMV is a leading cause of birth defects in the U.S., and Moderna estimates that its annual peak sales for the vaccine could be between $2 billion and $5 billion domestically. The company pulled up its estimate for the timing  of the first interim analysis of results from its phase 2 trial of mRNA-1647 to Q3 of this year, and described plans for a pivotal phase 3 trial to begin in 2021.

Moderna's initial public offering was the largest ever for a biotech when it debuted in December 2018. The company's ability to develop a vaccine candidate for SARS-CoV-2 so rapidly seems to have revived investor interest in this medical pioneer, which has built a platform for developing treatments based on messenger RNA -- an entirely new class of medicines.

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$123.64 (-0.55%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.